• Cy3 NHS ester (non-sulfonated) Guide

  2026-08-28

  Cy3 NHS ester (non-sulfonated), SKU A8100, provides an orange fluorescent NHS-ester reagent for labeling amino groups in proteins, peptides, oligonucleotides, and DNA. It is appropriate for workflows that tolerate DMSO or DMF, but not for strictly aqueous labeling or biomolecules that are highly sensitive to organic co-solvents.

• Bay 11-7821 for NF-κB Inflammation Assays

  2026-08-28

  Bay 11-7821 (BAY 11-7082) provides a practical pharmacological way to test IKK-dependent NF-κB signaling alongside TLR2/TLR4 inflammation models. This workflow-focused guide covers compound handling, monocyte cytokine assays, reporter experiments, apoptosis applications, and troubleshooting for reproducible cancer research.

• Lactate–HMGB1 Signaling in Polymicrobial Sepsis

  2026-08-27

  Yang and colleagues identified lactate as an active regulator of macrophage HMGB1 release rather than only a severity biomarker. The study links lactate uptake to HMGB1 lactylation, acetylation, exosomal secretion, endothelial barrier disruption, and poorer outcomes in polymicrobial sepsis.

• Q-VD-OPh for Reliable Apoptosis Assays

  2026-08-27

  This scenario-driven guide shows how Q-VD-OPh, SKU A1901, can help separate caspase-dependent apoptosis from metabolic suppression, mitophagy, and handling-related cell loss. It covers assay design, cryopreservation workflows, data interpretation, formulation, and practical supplier selection.

• Q-VD-OPh for Reliable Apoptosis Assays

  2026-08-26

  This scenario-driven guide explains how Q-VD-OPh, a cell-permeable pan-caspase inhibitor, can clarify apoptosis mechanisms, support post-thaw viability studies, and improve interpretation of complex cell assays. It includes practical solvent, storage, control, and vendor-selection considerations for SKU A1901.

• miR-196a Drives EAC via the MYC/TERT/NFκB Axis

  2026-08-26

  A 2025 Molecular Oncology study shows that miR-196a is not merely a progression marker in Barrett’s esophagus but an active driver of aggressive esophageal adenocarcinoma behavior. By linking NFKBIA, VCP, c-MYC, TERT, and NFκB signaling to epithelial-to-mesenchymal transition and motility, the work provides a mechanistic framework for studying disease progression and therapeutic response.

• Bestatin (Ubenimex): Assay Workflows

  2026-08-25

  Build more interpretable aminopeptidase activity measurement, apoptosis assay, and multidrug resistance workflows with Bestatin (Ubenimex). This guide connects enzyme selectivity and structure-informed inhibitor design to practical cancer research controls, dosing, and troubleshooting.

• Telatinib: Designing Better Angiogenesis Assays

  2026-08-25

  Telatinib (BAY 57-9352) is a multi-kinase inhibitor for dissecting VEGFR-driven angiogenesis, tumor-cell invasion, and stromal signaling. This guide goes beyond compound description to show how its target breadth should shape assay design and interpretation in TNBC and solid-tumor research.

• Luminescent ATP Cell Viability Assay Kit I Workflow

  2026-08-24

  Build faster cell viability measurement workflows for ferroptosis, proliferation, and drug-response studies with ATP-dependent luciferase luminescence detection. The kit combines a 10–30,000-cell linear range with a no-prelysis format, making it especially useful for resolving combination-treatment effects such as ciprofloxacin plus RSL3.

• Caspase-3 Fluorometric Assay Kit in RCC Apoptosis

  2026-08-24

  Use DEVD-AFC fluorescence to quantify executioner caspase activity in drug-treated renal cancer cells, then connect the signal to mitochondrial stress, ROS, and autophagy controls. This workflow turns a rapid apoptosis assay into a mechanistic experiment with practical normalization and troubleshooting guidance.

• 3-Bromopyruvate Reverses Cetuximab Resistance in CRC

  2026-08-23

  The 2023 Cancer Gene Therapy study shows that combining 3-bromopyruvate with cetuximab can suppress cetuximab-resistant colorectal cancer models through coordinated ferroptosis, autophagy, and apoptosis. Its mechanistic contribution is the identification of FOXO3a restoration and downstream AMPKα/pBeclin1 and PUMA signaling as a potential framework for studying resistance reversal.

• Septin4, VHL, and HIF-1α in Cardiomyocyte Apoptosis

  2026-08-22

  The reference study identifies HIF-1α as a previously unrecognized Septin4-interacting protein in hypoxia-exposed cardiomyocytes and shows that Septin4 strengthens VHL-dependent HIF-1α degradation. Its findings connect a mitochondrial proapoptotic protein to oxygen-sensing proteostasis, providing a mechanistic framework for studying hypoxia-inducible factor stabilization in cardiac injury models.

• Anlotinib Hydrochloride: From Target to Tumor Model

  2026-08-21

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor with a distinctive profile across receptor pharmacology, angiogenesis assays, and translational cancer research. This guide connects quantitative endothelial readouts with disease-model interpretation and highlights how a case report can improve experimental decisions.

• Pregnenolone Carbonitrile: Translational PXR Insight

  2026-08-20

  Pregnenolone Carbonitrile is more than a benchmark inducer of CYP3A. This thought-leadership analysis connects rodent PXR activation with gut–liver signaling, YAP-dependent hepatoprotection, hepatic stellate cell biology, and practical translational study design.

• ddhCTP: A Mechanism-First Guide to Antiviral Assays

  2026-08-20

  ddhCTP is a chain-terminating nucleotide analog that helps researchers distinguish direct RdRp inhibition from broader Viperin-mediated antiviral effects. This guide translates recent coronavirus findings into a mechanism-first framework for flavivirus studies, HEK293T assays, and antiviral drug development.

8773 records 1/585 page Next 12345 下5页 Last page